Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04579757
Title Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hutchison Medipharma Limited

gastric adenocarcinoma

malignant fibrous histiocytoma

lung small cell carcinoma

gastroesophageal junction adenocarcinoma

Advanced Solid Tumor

alveolar soft part sarcoma

rectum adenocarcinoma

colon adenocarcinoma

neuroendocrine tumor


Surufatinib + Tislelizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.